Biotech · Private company
Qlaris Bio, Inc.
Track this companyFree. Adds Qlaris Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs19From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline19
- Latanoprost (0.005%)Phase 3 · OAG - Open-Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111-FDCPhase 3 · OAG - Open-Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: QLS-111 ophthalmic solution, (0.015%)Phase 2 · Primary Open Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: QLS-111 ophthalmic solution, (0.03%)Phase 2 · Primary Open Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: QLS-111 ophthalmic solution, (0.075%)Phase 2 · Primary Open Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-101Phase 2 · Primary Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- QLS-101Phase 2 · Normal Tension Glaucoma (NTG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-101 ophthalmic solution, 2.0 %Phase 2 · Sturge-Weber SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- QLS-101ophthalmic solution 1%Phase 2 · Sturge-Weber Syndrome (SWS)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-101ophthalmic solution 2%Phase 2 · Sturge-Weber Syndrome (SWS)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111 Ophthalmic Solution (0.015%)Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111 Ophthalmic Solution (0.075%)Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111 ophthalmic vehicle solutionPhase 2 · Primary Open Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111 vehicle ophthalmic solutionPhase 2 · Open-angle Glaucoma (OAG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111, 0.015%Phase 2 · Open-angle Glaucoma (OAG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111, 0.030%Phase 2 · Open-angle Glaucoma (OAG)ClinicalTrials.gov · fetched Nov 12, 2026
- QLS-111, 0.075%Phase 2 · Open-angle Glaucoma (OAG)ClinicalTrials.gov · fetched Nov 12, 2026
- Timolol MaleatePhase 2 · Primary Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Timolol maleate PF 0.5% ophthalmic solutionPhase 2 · Normal Tension Glaucoma (NTG)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionPHASE2_PHASE3 · COMPLETED · started Mar 18, 2026ClinicalTrials.gov NCT07354516 · fetched Nov 12, 2026
- Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel DilationPHASE2 · COMPLETED · started Feb 20, 2026ClinicalTrials.gov NCT07354477 · fetched Nov 12, 2026
- Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT PatientsPHASE2 · COMPLETED · started Apr 21, 2024ClinicalTrials.gov NCT06249152 · fetched Nov 12, 2026
- Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT PatientsPHASE2 · COMPLETED · started Mar 5, 2024ClinicalTrials.gov NCT06016972 · fetched Nov 12, 2026
- Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)PHASE2 · COMPLETED · started Nov 23, 2022ClinicalTrials.gov NCT05495269 · fetched Nov 12, 2026
- A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101PHASE2 · COMPLETED · started Oct 19, 2021ClinicalTrials.gov NCT04947124 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Tolerability of QLS-101 in NTGPHASE2 · COMPLETED · started Sep 15, 2021ClinicalTrials.gov NCT04857827 · fetched Nov 12, 2026
- Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).PHASE2 · COMPLETED · started Mar 31, 2021ClinicalTrials.gov NCT04830397 · fetched Nov 12, 2026